| FRI-3 | A systematic review of digital health tools and early real-world experience with HepB&Me application in chronic hepatitis B to tackle the unmet clinical need | Almuthana Mohamed | |
| THU-3 | Evolving impact of alcohol and abdominal adiposity on liver mortality in Finland over four decades: implications for public health interventions | Fredrik berg | |
| SAT-3 | Risk of advanced fibrosis and cancer in a population-based colorectal cancer screening program: implications for EASL case-finding strategies | David Marti-Aguado | |
| WED-8 | Perspectives of people living with hepatitis B towards long-acting antivirals: a global study | Su Wang | |
| FRI-10 | Decentralised HBV, HCV, and HIV screening among migrant and refugee populations in Portugal and Spain: results from VH-COMSAVAC | Aina Nicolàs Olivé | |
| FRI-12 | Low treatment rates observed in an analysis of the chronic hepatitis B care cascade at a tertiary medical center in a major metropolitan area in the US | Kevin Pak | |
| SAT-12 | Patient pathways for rare liver diseases: development of a European template | Sarah Raevens | |
| FRI-13 | Prevalence and socioeconomics of hepatitis D virus coinfection in two Southern California counties | Kevin Pak | |
| FRI-15 | Predictors of hepatitis B infection and vaccination coverage in sub-Saharan Africa: case studies from Gabon and Mauritania using Demographic and health Survey data | Jodi Palmer | |
| SAT-15 | Multidisciplinary assessment of unemployment risk factors in liver transplant recipients: final results of the RICReaTI project | Margherita Saracco | |
| TOP-16 | Socio-demographic inequalities on the UK liver transplant waiting list over time: the impact of prognostic scores and candidate selection schemes | Ji Jade King | |
| TOP-17 | Feasibility and outcomes of liver health checks in community alcohol services | Daniel Gutmann | |
| TOP-18 | Increased diagnosis and risk stratification for MASLD in primary care over the last 20 years: real-world evidence from over 11.7 million individuals in the UK | Huei-Tyng (Philippe) Huang | |
| THU-19 | Sexual function in chronic liver disease: a case-control study | Yooyun Chung | |
| WED-20 | Evaluation of sex-based differences on hepatitis B, C and D viruses´ disease burden and cascade of care in Italy | Samantha Hall | |
| THU-20 | An interpretable artificial intelligence framework for cardiovascular risk prediction in metabolic dysfunction-associated steatotic liver disease: LiverCARD | antonio cirella | |
| THU-22 | Trends in hospitalizations and in-hospital mortality due to primary biliary cholangitis in Brazil (2015–2024): a decade of real-world evidence from the public unified health system | Cláudia Couto | |
| SAT-22 | Trends in mortality due to liver neoplasms in Portugal (2013-2022): a decade of rising challenges | Mario Jorge Silva | |
| THU-27 | Stable alcohol consumption over time in older adults, assessed by PEth | Marie Fredriksson | |
| WED-29 | Population-based hepatitis C screening and elimination program in Lithuania: may it affect the incidence of hepatocellular carcinoma? | Limas Kupcinskas | |
| SAT-31 | Validated early detection metrics reduces the population requiring liver fibrosis screening | Laurens Van Kleef | |
| TOP-33 | Non-genetic determinants of hepatitis B surface antibody disappearance in Taiwan´s vaccinated generations | CHUN-YI CHANG | |
| SAT-35 | Impact of fibrotic MASH as a new indication on semaglutide eligibility in the U.S. adult population | Laurens Van Kleef | |
| SAT-36 | Artificial intelligence in scientific abstract review: complement or contradiction to human judgment? Insights from a Latin American hepatology cohort | Maria Lynch-Mejia | |
| SAT-37 | Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study | Juan Vaz | |
| THU-38 | Real-world epidemiology and clinical outcomes in MASLD: A 20-year nationwide analysis of over 23 million individuals in Taiwan´s national health insurance research database | Huei-Tyng (Philippe) Huang | |
| WED-38 | From control to elimination of HCV infection: the experience in prisons of Catalonia, Spain | Andrés Marco | |
| SAT-38 | Socioeconomic disparities in access to curative treatment among individuals with surveillance-detected hepatocellular carcinoma in Sweden: a nationwide cohort study | Juan Vaz | |
| THU-39 | Outcomes and all-cause mortality in people with MASLD in UK primary care: a real-world matched cohort study of 1.8 million individuals | Huei-Tyng (Philippe) Huang | |
| SAT-39 | Burden, trends and projections of liver cancer in China and G20 countries: a comparative study based on the global burden of disease database 2023 | Yikai Wang | |
| SAT-40 | Burden, trends and projections of cirrhosis in China and G20 countries: a comparative study based on the global burden of disease database 2023 | Yikai Wang | |
| LBP-41 | HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH and F2–F3 fibrosis: a 52-week phase 2b randomized, double-blind, placebo-controlled trial | Feng Xue | |
| SAT-42 | Estimation of liver fibrosis risk using non-invasive biomarker tests in people living with HIV and pre-diabetes in Tanzania | Trenton White | |
| THU-42 | Mental distress and social support in adult offspring of parents with alcohol-related liver disease compared to offspring of parents with a cancer diagnosis: a national health survey | Pernille Jessen | |
| THU-47 | Effectiveness of a smartphone-assisted lifestyle intervention program on weight reduction: a retrospective study | Stanislav Kravchuk | |
| WED-51 | Clinical characteristics of patients with low liver stiffness measurement (LSM) on VCTE and biopsy-proven at-risk MASH on biopsy | Elizabeth Brombosz | |
| FRI-54 | Community-based alcohol-related liver disease early recognition and assessment (CALDERA): effect on drinking behaviour, markers of liver injury and emergency hospital attendance | Ewan Forrest | |
| SAT-57 | Drug-induced liver injury: a survey among members of the society of liver disease in Africa | Maurizio Bonacini | |
| SAT-58 | Our experience of immune-mediated hepatotoxicity: five-year data from a London cancer centre | Annabelle Chung | |
| WED-62 | Definite fibrotic metabolic-dysfunction associated steatohepatitis in referrals at center in Denmark | Mark Berner Hansen | |
| FRI-62 | Impact of on-demand nalmefene–mediated alcohol reduction on liver function and noninvasive fibrosis and steatosis measures in patients with alcohol use disorder and metabolic dysfunction–associated alcohol-related liver disease | Yohei Koizumi | |
| TOP-63 | Prognostic performance of liver stiffness changes in patients with biopsy-proven cirrhosis secondary to metabolic dysfunction-associated steatohepatitis | Jimmy Che-To Lai | |
| TOP-65 | Universal FIB4 screening, automated secondary care referral, new cACLD & HCC identified; benefits of integrated MASLD screening within the precision iDiabetes platform | Damien Leith | |
| THU-68 | Alarmin interleukin-33 protects against liver injury and promotes hepatocyte proliferation in acute liver failure | Mengqi Li | |
| THU-70 | Construction of engineered biliary trees with P-glycoprotein efflux function and enhanced resistance to drug-induced injury | Shiwen Ma | |
| SAT-70 | Clinical relevance of albumin binding kinetics in patients undergoing extracorporeal albumin detoxification | Stine Koball | |
| WED-73 | Metabolic and cognitive effects of a 6-month dietary intervention in patients with MASLD: a prospective study | Gian Paolo Caviglia | |
| WED-75 | Comparison of clinical care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes (T2D) in the dawn of effective pharmacological therapy | Wah Kheong Chan | |
| FRI-78 | Long-term mortality under the new steatotic liver disease classification | Sakkarin Chirapongsathorn | |
| FRI-79 | Higher socioeconomic position is associated with alcohol under-reporting relative to PEth | Helle Schnefeld | |
| WED-85 | Deep learning integration of nuclear magnetic resonance metabolomics and NASH-FibroTest biomarkers improves blood-based prediction of liver fat measured by magnetic resonance imaging | Olivier Deckmyn | |
| THU-87 | Liver metabolic stress and fibrosis modify APOE e4–associated cognitive vulnerability and amyloid burden | Young Hyeon Ahn | |
| SAT-87 | Individualised treatment benefit of double plasma molecular adsorption system in patients with liver failure | Yee Hui Yeo | |
| FRI-88 | Triglycerides identify a lower-risk phenotype and predict mortality in clinically suspected alcohol-associated hepatitis | Ana Suárez-Saro Fernández | |
| THU-90 | Missed opportunities to diagnose metabolic dysfunction associated and alcohol associated steatotic liver disease after incidental detection in the emergency department | Qusai Al Zureikat | |
| WED-91 | A new definition of burning-out MASLD using albumin and amino acid imbalance | Hideki Fujii | |
| SAT-92 | The single-cell landscape of MASLD-enriched liver sinusoidal endothelial | DAE WON JUN | |
| SAT-95 | Dysregulation of the E2F2-PCSK9 axis promotes MASLD progression and related cardiovascular disease | Maider Apodaka-Biguri | |
| TOP-96 | Can reliably measured transient elastography be trusted in obesity? Comparing the modifying effects of general and central adiposity in MASLD | Fredrik berg | |
| TOP-97 | Assessment of cardiometabolic comorbidities and the impact of glycemic and weight control on liver stiffness in advanced metabolic dysfunction-associated steatotic liver disease | Cautar El Maimouni | |
| WED-100 | A novel machine learning-based algorithm improves risk stratification of patients with MASLD compared to FIB-4 | Kamela Gjini | |
| FRI-100 | Cell-free DNA as a biomarker of liver fibrosis in alcohol-related liver disease | Paola Zuluaga Blanco | |
| FRI-102 | Hepatic stellate cell-derived Follistatin-like 3 ameliorates alcohol-induced liver injury via inhibition of Activin type II receptor signaling pathway | Gloria Alvarez-Sola | |
| SAT-103 | Epigenetic programming of metabolic liver disease by early-life nutritional overload | claudia bigas | |
| SAT-104 | Global analysis of protein post-translational modifications reveals novel regulatory mechanisms in steatotic liver disease | Virginia Aranda | |
| SAT-107 | Protease driven phenotypical changes in lipid associated macrophages attenuates metabolic dysfunction associated steatohepatitis progression | Júlia Cacho-Pujol | |
| THU-107 | Stronger association and causal link between visceral adipose tissue and metabolic dysfunction-associated steatotic liver disease in women, particularly after menopause | Yutian Cao | |
| WED-115 | Prediabetes identifies a high-risk subgroup for advanced liver fibrosis in non-diabetic MASLD: a non-invasive risk stratification study | Trung Huynh | |
| WED-118 | Prognostic significance of a 5 kPa absolute change in liver stiffness measurements (LSM) to predict liver-related events in patients with compensated advanced metabolic dysfunction-associated steatotic liver disease (MASLD) | Xinrui Jin | |
| THU-119 | Association between sex and long-term clinical outcomes in metabolic dysfunction-associated steatotic liver disease | Pojsakorn Danpanichkul | |
| SAT-121 | The chronic environmental exposure to Bisphenol A influences trained immunity-related pathways and induces immunometabolic innate cells reprogramming, promoting the metabolic dysfunction associated steatotic liver disease (MASLD) progression | Marcello Dallio | |
| WED-122 | Optimal cut-off of 2D shear wave elastography for ruling out significant hepatic fibrosis in MASLD: a meta-analysis and machine learning | DAE WON JUN | |
| FRI-126 | Binge alcohol exposure induces neutrophil extracellular trap associated injury in the proximal small intestine | Scott Minchenberg | |
| WED-127 | Emerging indices outperform traditional fibrosis scores in young MASLD across divergent screening goals | Ahlim Lee | |
| TOP-128 | An artificial intelligence model to better predict hepatocellular carcinoma risk in patients with metabolic dysfunction-associated steatotic liver disease: a large-scale 20-year cohort study | Ming-Ying Lu | |
| THU-131 | Vitamin D insufficiency is associated with liver fibrosis development in people with HIV | Francesca Farina | |
| THU-133 | Depression and anxiety levels are higher in obese women than in men in a cohort of MASLD patients | Marta Guariglia | |
| SAT-134 | Ultrastructural analysis of transjugular biopsies in metabolic dysfunction-associated steatotic liver disease identifies core hepatocellular stress adaptations | Jose Fortea | |
| SAT-139 | The liver RNF43-Wnt/ß-catenin pathway remotely regulates the intestinal inflammation repair pattern through bile acid reprogramming | Ying Geng | |
| THU-140 | Steatotic liver disease as an upstream risk factor for the development of metabolic syndrome–related disorders: a 7-year health checkup cohort study in Japan | Yoshihiro Kamada | |
| FRI-140 | Isotemporal associations of sedentary behavior and physical activity with health-related quality of life in patients with metabolic dysfunction-associated steatotic liver disease | Abdullah Alansare | |
| FRI-147 | Efficacy of a therapeutic physical exercise program in patients with metabolic dysfunction–associated steatotic liver disease: a randomized, open-label, bicenter study (SteatoAPA) | Rodolphe Anty | |
| SAT-147 | Lack of MASP-3 ameliorates liver injury and fibrosis in diet-induced fatty liver via modulation of apoptosis and inflammatory pathway in mice | Manabu Hayashi | |
| THU-147 | Long-term association between Helicobacter pylori serostatus changes and incident metabolic dysfunction–associated steatotic liver disease | HAE YEON KANG | |
| THU-149 | Impact of endothelial dysfunction on disease progression in patients with MASLD and microalbuminuria | Hijran Khidirova | |
| THU-151 | MASLD and coronary calcification: how Bayesian analysis supports the association | Florian Koutny | |
| FRI-151 | Which comes first: GLP-1 RA vs resmetirom in MASH real world practice | Ana Maria Davila Morales | |
| FRI-153 | Treatment with naltrexone/bupropion enhances lifestyle-induced improvements in hepatic steatosis in adults with overweight/obesity | Carmen Dietvorst | |
| WED-154 | FIB-4 reflex testing in patients with diabetes mellitus at the primary care level allows calculation of referral rates to specialized care and allocation of resources | Eva Katharina Messer | |
| FRI-157 | Habitual aspirin use and MRI-derived liver fat and fibroinflammation | Qi Feng | |
| THU-159 | Brief alcohol counseling in steatotic liver disease: a single-center observational study of six-month changes in alcohol use, noninvasive liver metrics, and quality of life | Erica Nicola Lynch | |
| TOP-161 | Maternal metabolic dysfunction-associated steatotic liver disease rewires placental-fetal selenium crosstalk and mediates fetal liver insulin resistance | Simran Sharma | |
| FRI-163 | Cost-effectiveness of resmetirom treatment, aligned with practice guidance, for suspected ´At-Risk MASH´ identified by transient elastography without histologic confirmation | DAE WON JUN | |
| SAT-164 | Imeglimin attenuates liver injury in a nondiabetic mouse model of MASH by restoring mitochondrial function | Kosuke Kaji | |
| SAT-165 | Multi-compartment dissection of bile acid remodeling reveals mechanistic drivers of MASLD progression | DAE WON JUN | |
| WED-166 | Is perfection the enemy of good? A streamlined screening strategy for metabolic dysfunction-associated steatotic liver disease in the community | TD Clara Nguyen | |
| WED-167 | The influence of stress factors on the state of the intestinal microbiota and intestinal epithelial permeability in patients with metabolic dysfunction-associated steatotic liver disease | Yana Nikiforova | |
| THU-171 | The journey of MASLD: the implementation gap between guidelines and primary care in linkage to care | DAE WON JUN | |
| SAT-172 | GPR84 antagonism shifts liver macrophage polarization from M1 to M2, increases liver triiodothyronine, and improves cholesterol levels and hepatic steatosis in a high-fat diet metabolic dysfunction-associated steatohepatitis mouse model | Martin Leduc | |
| THU-173 | Estimated glomerular filtration rate and urine albumin-creatinine ratio trajectories in young adulthood and midlife metabolic-dysfunction associated steatotic liver disease: the coronary artery risk development in young adults study | Seong Park | |
| WED-174 | Machine learning prediction of liver fibrosis in patients with metabolic dysfunction associated steatotic liver disease (MASLD) | Grazia Pennisi | |
| WED-179 | Head-to-head comparison between FibroTest and ELF, for the fibrosis diagnostic in outpatients with type-2 diabetes, using Bayesian latent class models | Valentina Peta | |
| THU-179 | Ethnic differences in non-invasive tests, disease severity, and liver-related outcomes in a diverse Canadian population with metabolic dysfunction-associated steatotic liver disease | Keyur Patel | |
| THU-182 | The relationship between endothelial dysfunction, insulin resistance, and metabolic associated steatotic liver diseases | Kateryna Pivtorak | |
| FRI-184 | Effects of SGLT-2 inhibitors on clinical outcomes in patients with MASLD and type 2 diabetes mellitus: a nested case-control study using LIFE study data | Eiichi Ogawa | |
| WED-185 | Comparison of MASLD characteristics in patients with type 1 and 2 diabetes mellitus | Donovan Richelle | |
| WED-189 | Lysosomal acid lipase activity as a marker of advanced fibrosis in steatotic liver disease: a prospective study | Tarek Saadi | |
| THU-191 | Assessment of maternal and fetal outcomes of pregnancy in metabolic associated fatty liver disease, a prospective cohort study | Hend Shousha | |
| TOP-193 | Serum glycomics at admission predict liver transplantation-free survival in patients with acetaminophen-induced acute liver failure | Lorenz Grossar | |
| SAT-198 | Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD | erika paolini | |
| SAT-201 | Single-cell integration of transcriptomics and mtDNA sequencing identifies pan-cellular mosaic mitochondrial heteroplasmy as a hallmark of MASH | Carlos Pirola | |
| FRI-204 | FB7033: A novel siRNA dual-targeting Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17ß13) and cell death-inducing DFF45-like effector B (CIDEB) exhibits potential for treatment of metabolic dysfunction-associated steatohepatitis (MASH) | Michael Wang | |
| FRI-205 | SGLT2 inhibitors and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Axel Wester | |
| WED-205 | Comprehensive risk assessment for gastrointestinal cancers in steatotic liver disease (MASLD, MetALD, and ALD) | Nobuharu Tamaki | |
| WED-211 | Prognostic value of liver stiffness measurement for liver-related events in metabolic dysfunction-associated liver disease-related compensated advanced chronic liver disease | Kessarin Thanapirom | |
| WED-215 | Simplified metabolic dysfunction associated fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis | Laurens Van Kleef | |
| WED-216 | Evaluating non-invasive screening strategies for identifying treatment-eligible fibrotic MASH in MASLD patients | Laurens Van Kleef | |
| THU-216 | Evaluating gastrointestinal bleeding risks and esophagogastroduodenoscopy requirement in low-risk hepatocellular carcinoma patients undergoing atezolizumab and bevacizumab: interim analysis | Laia Aceituno | |
| THU-217 | The VETC-associated trabecular subtypes in non-cirrhotic HCC is defined by loss of tumor suppressor and downregulation of ribosomal genes | Khushboo Agrawal | |
| THU-218 | Predicting transcatheter arterial chemoembolization response in hepatocellular carcinoma using a two-stage imaging framework with automated liver segmentation and bidirectional temporal difference modeling | Geng-Hao Bai | |
| TOP-224 | Inhibition of protein kinase C-? as a strategy to overcome steroid resistance in severe alcohol-related hepatitis | Manisha Yadav | |
| WED-225 | Real-world liver fibrosis screening patterns of adults with type 2 diabetes and cirrhosis: a population-based Canadian cohort | Cindy Wen | |
| FRI-225 | Durvalumab–Tremelimumab in advanced hepatocellular carcinoma: real-world data From the LOR-HCC (Lombardy, Italy real-world HCC group) | Lorenzo Canova | |
| THU-227 | Predicting decompensation in unresectable hepatocellular carcinoma on immunotherapy: the ARTE score | Lorenzo Canova | |
| WED-229 | Referral burden and second-tier testing in two-step algorithms for detecting significant hepatic fibrosis among Asian community-based type 2 diabetes mellitus | DAE WON JUN | |
| WED-232 | TP53/ARID1A-driven macrotrabecular and TERT/BAP1-enriched microtrabecular tumors represent two distinct histomorphological subtypes of non-cirrhotic hepatocellular carcinoma | Khushboo Agrawal | |
| WED-234 | Identification of novel therapeutic agents using patient-derived organoids in HCC | Reha Akpinar | |
| FRI-234 | Transjugular intrahepatic portosystemic shunt as a bridging strategy to hepatocellular carcinoma treatment in patients with refractory ascites or hydrothorax | Camille Imparato | |
| FRI-237 | First-line therapy in super-older adults with hepatocellular carcinoma: comparative effectiveness of Lenvatinib versus Atezolizumab-Bevacizumab | Masamichi Kimura | |
| THU-237 | Hepatocellular carcinoma risk prediction score : a novel artificial intelligence model for hepatocellular carcinoma risk assessment in hepatitis C patients | Eslam Elmasry | |
| FRI-244 | Efficacy of second-line therapies and the prognostic value of the crafity score in advanced hepatocellular carcinoma following Atezolizumab plus Bevacizumab failure: a real-world study | Jinpeng Li | |
| FRI-245 | Radiotherapy with Atezolizumab and Bevacizumab and Survival in Advanced Hepatocellular Carcinoma | Gyungsun Lim | |
| THU-246 | Machine learning-enhanced serum FTIR spectroscopy analysis for diagnosing hepatocellular carcinoma in cirrhotic patients | Elia Gigante | |
| SAT-246 | High burden of depression, sleep disturbance, and anhedonia in primary biliary cholangitis independent of fibrosis stage and prognostic scores | Gupse Adali | |
| FRI-249 | Real-world outcomes of sequential transarterial chemoembolization followed by Atezolizumab–Bevacizumab in patients with unresectable hepatocellular carcinoma | Soe Thiha Maung | |
| SAT-251 | S-adenosyl-L-methionine improves health-related quality of life in patients with primary sclerosing cholangitis and inflammatory bowel disease: a subanalysis of a randomized, placebo-controlled trial | Emil Bik | |
| WED-252 | Platelet-induced mitochondrial transfer promotes hepatocellular carcinoma progression | Shuangsuo Dang | |
| FRI-252 | First-line Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in Egyptian patients with unresectable hepatocellular carcinoma: a retrospective real-world study | Ehab F. Moustafa | |
| THU-253 | Study of the prevalence of hereditary hemochromatosis (HFE) and secondary causes of hiperferritinemia in patients participating in a bloodletting programme | Agustin Castiella | |
| THU-259 | Clinical characteristics of alpha-1 antitrypsin deficiency patients and coexistence of metabolic dysfunction-associated steatotic liver disease | Maria Del Barrio | |
| SAT-260 | True seronegative autoimmune hepatitis in adults is rare and overestimated | Francesca Colapietro | |
| THU-261 | Structured transition care program for chronic liver disease: a 6-Year clinical audit demonstrating superior outcomes | Victoria Ekstrom | |
| FRI-262 | Pathogenic MUC1? cholangiocytes drive fibrogenic crosstalk via the EFNA5–EPHA2 axis in cholestatic liver injury | Aishwarya Bhatnagar | |
| THU-265 | Quantitative histological evaluation reveals duct paucity in children with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype) | Malin Fromme | |
| FRI-266 | Identification of molecular targets from the interactome of primary sclerosing cholangitis and their therapeutic modulation | Claudia Fuchs | |
| FRI-268 | T helper cells influence the fate decision of facultative liver stem cells | Ben Higgins | |
| SAT-268 | Reassessing the utility of the Ferritin-IgG score in predicting complete biochemical response in patients with autoimmune hepatitis from the ColHai registry: is it truly useful? | Alvaro Diaz-Gonzalez | |
| THU-269 | Haemodynamic alterations associated with hepatic vascular malformations in hereditary haemorrhagic telangiectasia: a cohort study | Pernille Darre Haahr | |
| WED-271 | Circulating lipid signatures drive mitochondrial stress and inflammatory remodelling in non-cirrhotic MASLD-associated hepatocarcinogenesis | Jian Huang | |
| FRI-272 | Methyldopa reduces plasma bile acid concentrations in a murine model of estrogen-induced cholestasis | Dina Manna | |
| WED-272 | Enhanced detection of hepatocellular carcinoma using combined biomarker panels including alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxyprothrombin and the galad score | Van Trung Huynh | |
| SAT-274 | Long term prognostic impact of persisting histological activity despite biochemical remission in autoimmune hepatitis (AIH) | Sarah Flatley | |
| SAT-275 | Long-term extrahepatic mortality in autoimmune hepatitis: a cohort study | Sarah Flatley | |
| THU-276 | Safety of infliximab in sarcoidosis and effect on hepatic involvement – a retrospective cohort study | Elizabeth Low | |
| TOP-277 | Real-world effectiveness and safety of seladelpar in primary biliary cholangitis: a nationwide electronic health record-based study | Adrielly Martins | |
| TOP-278 | Factors associated with the development of primary biliary cholangitis in individuals with antimitochondrial antibodies: a spanish multicenter study | Alvaro Diaz-Gonzalez | |
| WED-282 | Visualizing and quantifying brain copper retention in Wilson disease models: a 64Cu PET study | Nicole Antolini | |
| THU-283 | Exploring pregnancy among Wilson disease patients in Europe: results from a health-care providers´ exploratory survey from the ERN RARE-LIVER consortium | Zoe Mariño | |
| SAT-283 | Unmet needs of patients with primary biliary cholangitis in Greece: results from the preliminary analysis of the Hellenic autoimmune liver diseases study group | Nikolaos Gatselis | |
| WED-284 | High copper levels induce oxidative stress and inflammatory processes in a cell culture model of Wilson´s disease | Ruth Broering | |
| WED-287 | Hepatocyte-specific CNNM4 silencing alleviates liver injury in alpha-1 antitrypsin deficiency | Nerea Ferreiro | |
| THU-289 | Utility of using modified Leipzig score for diagnosis of Wilson´s disease in a resource-limited setting | Yumnah Riaz | |
| FRI-290 | Multi-omics analysis reveals zone-specific hepatocyte antigen presentation and pathogenic CD8+ T cells in autoimmune hepatitis | Han Wang | |
| TOP-292 | Statin use is associated with reduced cholangiocarcinoma risk in primary sclerosing cholangitis: a national EHR cohort study | Miki Scaravaglio | |
| TOP-294 | The number needed to treat with bezafibrate as second-line therapy to prevent liver transplantation or death in people with primary biliary cholangitis | Ellen Werner | |
| TOP-295 | Centrally-imprinted innate immune tolerance following colitis attenuates cholestatic liver disease: implications for gut-liver axis driven PSC-IBD pathogenesis | Rania Matthys | |
| TOP-296 | Liver-specific CNNM4 silencing alleviates fibrosis by restoring bile acids homeostasis in cholestatic preclinical models and human liver slices | Naroa Goikoetxea-Usandizaga | |
| THU-299 | Genome-wide association study to identify novel genetic variants associated with primary Budd-Chiari syndrome | Shalimar Shalimar | |
| SAT-302 | The mean corpuscular volume (MCV) is a surrogate for therapeutic azathioprine metabolites in patients with autoimmune hepatitis | Guan Sen Kew | |
| FRI-302 | Inhibiting cuproptosis mitigates cholangiocyte inflammation in primary biliary cholangitis | Yu-Jie Zhou | |
| TOP-309 | Genetic testing reveals hidden genetic diseases in adult patients with idiopathic chronic cholestasis and chronic hepatitis with unknown aetiology | Ignasi Olivas | |
| TOP-310 | Two-fold improvement of thrombosis regression rate after implementation of a multidisciplinary treatment protocol for acute superior mesenteric vein thrombosis | Sophie Ciere | |
| FRI-314 | Targeting TRIM54: a potential protective strategy against liver injury in cirrhosis | Fan-E Cheng | |
| SAT-323 | Impact of imaging surveillance on outcomes after cholangiocarcinoma diagnosis in primary sclerosing cholangitis | Adrielly Martins | |
| SAT-324 | Latent class analysis identifies three distinct patient phenotypes in primary sclerosing cholangitis: implications for clinical trial access and mental health screening | Adrielly Martins | |
| WED-324 | Human liver spatial transcriptomics reveals macrophage-driven antiviral responses distinguishing seronegative fulminant hepatitis from autoimmune hepatitis | Amber Bozward | |
| TOP-325 | Time-resolved single-cell profiling of liver fibrosis regression identifies monocyte-derived Kupffer cells as central mediators of resolution | Katharina Bonitz | |
| FRI-330 | The platelet-derived growth factor receptor beta binding vector "Fibrobody®", for clinical targeting of liver fibrosis | Sylvia Klomp | |
| WED-332 | Hepatitis B virus specific T cell immunity to guide discontinuation of nucleoside analogue therapy in hepatitis B e antigen negative chronic hepatitis B | Raquel Encijo-Heredia | |
| SAT-334 | Rifaximin ameliorates liver fibrosis and hepatocarcinogenesis in experimental MASH by inhibiting the gut–liver axis and Epiregulin–IL-8–driven angiogenesis | Kosuke Kaji | |
| WED-337 | Retinoids reprogram TREM2? monocyte-derived macrophages toward a restorative phenotype via redox control to attenuate liver fibrosis | Kyurae Kim | |
| THU-338 | MAVS-dependent type I interferon mediated non-viral liver injury and hepatocarcinogenesis upon hepatic autophagy inhibition | Lea Aylin Yücel | |
| TOP-342 | Hepatic B cells interact with invariant natural killer T cells via CD40 to stimulate hepatic stellate cells | Jihyo Byun | |
| TOP-344 | SIRT4 enhances NK cell cytotoxicity against hepatic stellate cells and reverses liver fibrosis via the AMPKa/p53/NKG2DL axis | Huan Chen | |
| WED-345 | PD-1+ follicular helper T cells as the key discriminator: a combined model with plasmablasts for distinguishing autoimmune hepatitis from drug-induced liver injury | Zikun Ma | |
| SAT-348 | Diet and exercise mitigate MASLD and exert beneficial effects on skeletal muscle via organ crosstalk in diet-induced obese mice | Vanessa Souza-Mello | |
| WED-352 | Collectin-11 of the lectin pathway mediates complement-dependent hepatic ischemia-reperfusion injury in mice | Tatsuro Sugaya | |
| SAT-353 | Gut microbiota metabolite butyrate ameliorated acute-on-chronic liver failure by regulating macrophage polarization | Jing Xiao | |
| WED-355 | Targeting the STING pathway as a strategy to suppress hepatitis B virus replication | Mingyuan Zhang | |
| WED-356 | VISTA deficiency exacerbates the development of acute-on-chronic liver failure by promoting Tc1 differentiation | Yao Zhang | |
| TOP-359 | Prospective multicenter evaluation of prototype deep learning algorithms versus liver imaging reporting and data system (LI-RADS) criteria in diagnosing hepatocellular carcinoma on computed tomography | Rex Wan-Hin Hui | |
| SAT-361 | Bridging the gap in primary sclerosing cholangitis care: results from a patient survey | Adrielly Martins | |
| THU-362 | mRNA COVID-19 vaccination shortly after PD-1/PD-L1 inhibitor Is associated with better survival in liver cancer: a Mayo Clinic platform study | Yuting Huang | |
| THU-363 | Serum exosome-related lipids could detect MASLD-associated hepatocellular carcinoma | Jian Huang | |
| THU-364 | Intensive care admission patterns and outcomes in hepatocellular carcinoma patients on systemic therapy | Rex Wan-Hin Hui | |
| FRI-370 | Prognostic and predictive value of single-nucleotide polymorphism signature in patients with resected hepatocellular carcinoma: a multicentre retrospective study | Xiao-Peng Tian | |
| TOP-373 | A confidence-aware artificial intelligence pathology model for cholangiocarcinoma diagnosis | Yue Cheng | |
| TOP-375 | Prognostic impact of neoplastic portal vein thrombosis and extrahepatic metastases in advanced hepatocellular carcinoma receiving Atezolizumab–Bevacizumab: a multicenter real-world study | Filippo Cattazzo | |
| FRI-379 | Comparison of surgical resection, percutaneous ablation, and transarterial chemoembolization for hepatocellular carcinoma patients with recompensated cirrhosis: a multicenter, retrospective, cohort study | Can Zhang | |
| WED-380 | Single-cell transcriptomic profiling of endothelial-to-mesenchymal transition in MASLD-associated liver carcinogenesis | Victoria Priori | |
| THU-382 | Performance of HCC risk scores in patients with advanced chronic liver disease: a multicenter cohort study | Mohamed Moussa | |
| FRI-382 | Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in hepatic encephalopathy | Clelia Asero | |
| THU-383 | Addition of the GAAD score to imaging improves classification of non-cirrhotic focal liver lesions | Mohamed Moussa | |
| WED-385 | Galectin-3 inhibition supports HCC growth via pro-tumorigenic liver reprogramming | Paul Schneider | |
| FRI-385 | Serum-conditioned nanoplastics trigger hepatocyte injury and inflammation in human liver tissue | Paula Boeira | |
| THU-387 | Identify liver tumors from ultrasound images through ensemble learning integrated with the ordered weighted averaging operator | Hsiao-Ching Nien | |
| FRI-388 | Maladaptive emergency myelopoiesis is already activated in patients with the less severe forms of acutely decompensated cirrhosis, and its amplification drives progression towards severity | Zhujun Cao | |
| TOP-390 | Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma | Paula Olaizola | |
| FRI-395 | Recapitulating cirrhosis in vitro using a primary liver microphysiological system and patient plasma profiling | Laura de Jong | |
| FRI-397 | Increased ceftriaxone exposure in hospitalised patients with decompensated cirrhosis compared to patients without cirrhosis revealed by population pharmacokinetic modelling (TACTILE study) | Solaiman Ezzafzafi | |
| THU-397 | Imaging spectrum of giant hepatic hemangioma with diffuse hepatic hemangiomatosis: nine case series | Ki Choon Sim | |
| THU-398 | Hepatocellular carcinoma in Budd Chiari syndrome: characteristics and risk factors | MARINELA STOIAN | |
| TOP-407 | Development and validation of a novel pretreatment MRI-based radiomic model to predict progression after thermal ablation in early stage hepatocellular carcinoma using data from two randomised control trials | Mathew Vithayathil | |
| TOP-408 | Efficacy and feasibility of neoadjuvant immunotherapy in hepatocellular carcinoma | Sarah Cappuyns | |
| FRI-409 | Insulin-like growth factor 1 suppression worsens with cirrhosis severity and mortality, and therapeutic restoration improves outcomes in decompensated cirrhosis: a clinical-experimental study | Parminder Kaur | |
| SAT-411 | Long-term outcomes of autoimmune hepatitis: complications, cancer risk and survival in a large nationwide swedish cohort | Richard Thörn | |
| FRI-411 | Systemic markers of fibroblast- and immune cell activity in post-TIPS endotyping within patients with severe clinical evolution | Diana Leeming | |
| WED-412 | CAND1 as a novel therapeutic target in pediatric hepatoblastoma: linking NEDDylation to tumor progression | Leidy Estefanía Zapata-Pavas | |
| THU-414 | Exploring practices and attitudes towards stopping hepatocellular carcinoma surveillance: a multinational clinician survey with over 500 respondents | Georgia Zeng | |
| WED-415 | Clostridioides difficile mortality in cirrhotic patients matches other bacterial infections in the antimicrobial resistance era | Alexandra Alexopoulou | |
| SAT-416 | Metabolic syndrome as a determinant of inadequate biochemical response to ursodeoxycholic acid in primary biliary cholangitis | Christos Triantos | |
| WED-417 | Is 100 the new 250? Ascites fluid PMN >100 has the highest predictive value and odds for 30-day mortality in a national cirrhosis cohort undergoing paracentesis | Jasmohan Bajaj | |
| SAT-417 | Presence of myopathy in patients with primary biliary cholangitis | Yigit Sahin | |
| WED-418 | Dynamic assessment of the AMMON model can guide preventative therapies of patients at risk of liver-related events | Maria Pilar Ballester | |
| SAT-419 | Recurrence rate and clinical outcomes for recurrent primary sclerosing cholangitis after liver transplantation: a systematic review with meta-analysis | Lisa Laforce - van Lierop | |
| TOP-422 | Epigenetic dysregulation of the IL1B-driven inflammatory program drives resistance to anti–PD-1 therapy in hepatocellular carcinoma | Wenying Qiao | |
| TOP-423 | Therapeutic plasma exchange improves short-term survival in acute on chronic liver failure: a randomised controlled trial | Sagnik Biswas | |
| THU-426 | Efficacy and safety of endoscopic and endovascular interventions for secondary prophylaxis of gastric varices in patients with cirrhosis: systematic review and individual patient data meta-analysis | Sagnik Biswas | |
| WED-426 | Effects of GLP-1 receptor agonists on the progression of metabolic chronic liver disease. | Montserrat Camps Fajol | |
| SAT-428 | Differentiating acute-onset autoimmune hepatitis from drug-induced autoimmune-like hepatitis: a multicenter study and score development | Haoyu Wen | |
| WED-430 | Computed tomography-defined sarcopenic obesity: an emerging risk factor for cardio-cerebrovascular mortality in cirrhosis | Yanhua Chen | |
| FRI-434 | Targeting disrupted immunometabolism-induced mitochondrial bioenergetic failure using YAQ006 and YAQ005 reduces mortality in ACLF | Supachaya Sriphoosanaphan | |
| FRI-435 | Ammonia-induced mitochondrial bioenergetic failure is driven through a TLR4-dependent mechanism that specifically targets Complex IV | Supachaya Sriphoosanaphan | |
| THU-435 | Prevalence and risk factors of esophageal and gastroesophageal varices in myeloproliferative neoplasm patients with portal hypertension in a tertiary government hospital: a 5-year cross-sectional study | Sam Fandood | |
| FRI-441 | Targeting glycolytic rewiring rescues liver sinusoidal endothelial cell mitochondrial bioenergetics and vascular barrier integrity mitigates endotoxin mediated portal hypertension in cirrhosis | Vaibhav Tiwari | |
| SAT-441 | One in four adults have already developed cirrhosis at the time of primary biliary cholangitis diagnosis among a national cohort of veterans in the United States | Robert Wong | |
| FRI-444 | Data-driven biomarker phenotypes refine risk stratification in advanced chronic liver disease | Adrian Wunderbaldinger | |
| WED-444 | Comparative assessment and external validation of ultrasound-derived quadriceps indices against bioelectrical impedance analysis for sarcopenia screening in chronic liver disease | Paolo Gallo | |
| SAT-445 | Clinical characteristics and predictors of poor biochemical response in patients with primary biliary cholangitis: a single-centre study from Xinjiang, China | Caihua Chang | |
| FRI-447 | Fenofibrate is associated with improvement in chronic cholangiopathy after liver transplantation: a single-center experience | Fredrik berg | |
| FRI-448 | Donor and recipient pharmacogenetic variation at the POR locus is associated with acute rejection and biliary strictures after liver transplantation | Fredrik berg | |
| THU-448 | Diabetes is an independent risk factor for hepatic encephalopathy and death in patients undergoing TIPS placement | Lukas Hartl | |
| THU-449 | TIPS facilitates recovery from different types of hepatorenal syndrome and may improve clinical outcomes in patients with HRS-AKI | Lukas Hartl | |
| SAT-449 | Alterations in primary hemostasis in patients with liver cirrhosis and bacterial infection | Alexandra Alexopoulou | |
| SAT-451 | Validation of consensus liver failure cut offs to predict 30-day mortality in a nationwide inpatient cirrhosis cohort | Jasmohan Bajaj | |
| SAT-452 | Immune failure in ACLF: validation of consensus definitions in two large cohorts of inpatients with cirrhosis | Jasmohan Bajaj | |
| FRI-452 | Intrahepatic low shear–induced mitochondrial redox dysfunction in liver sinusoidal endothelial cells drives microvascular dysfunction and contributes to acute portal hypertension | Rajni Yadav | |
| WED-453 | Elevated growth differentiation factor 15 reflects disease-driving mechanisms in cirrhosis and predicts liver disease progression and mortality | Benedikt Hofer | |
| TOP-454 | Impact of apixaban on hepatic decompensation in cirrhosis (ApiHep): a randomized controlled trial | Ayush Agarwal | |
| TOP-455 | Pre-treatment serum albumin concentration predicts clinical outcomes in patients with cirrhosis receiving long-term albumin | Enrico Pompili | |
| TOP-456 | Prognostic impact and predictive factors of cardiac decompensation following TIPS implantation in cirrhosis– data from the multicenter CARTIPS study | Medizinische Hannover | |
| THU-458 | Quantifying the morbidity and mortality of decompensated liver cirrhosis in Australia | Angus Jeffrey | |
| FRI-461 | Safety and efficacy of GLP-1 receptor agonists in liver transplant recipients: a multi-national experience | Chiara Becchetti | |
| THU-463 | Combining different non-invasive tests stratifies the risk of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD) | Jimmy Che-To Lai | |
| THU-466 | The differential effects of terlipressin on serum sodium trajectories are mediated by ascites status, treatment indication and baseline sodium | Dorothy Liu | |
| FRI-467 | Secretin therapy during ex-situ normothermic liver machine perfusion: a critical factor for restoration of bile duct physiology and the protective "bicarbonate umbrella" | Roberto Broere | |
| FRI-468 | Clinical outcomes of sequential hypo- and normothermic machine perfusion versus abdominal normothermic regional perfusion for extended criteria donors in liver transplantation: a single center comparison | Roberto Broere | |
| FRI-473 | The impact of extending preservation time of extended criteria liver grafts through hypothermic oxygenated machine perfusion prior to normothermic machine perfusion on viability assessment and clinical outcomes | Roberto Broere | |
| FRI-476 | Triglyceride-based insulin resistance indices and post-transplantation diabetes mellitus after liver transplantation | Mateo Chvatal-Medina | |
| WED-476 | Prevalence, risk factors, and clinical outcomes of micronutrient deficiencies in patients with cirrhosis: a prospective cohort study | &3660;&3660;Narisorn Lakananurak | |
| FRI-477 | Triglyceride-rich lipoprotein cholesterol and risk of post-transplant diabetes in liver transplant recipients | Mateo Chvatal-Medina | |
| FRI-478 | Synergism of trimethylamine n-oxide and lipoprotein insulin resistance with post-transplantation diabetes after liver transplant | Mateo Chvatal-Medina | |
| WED-478 | Shear wave elastography combined with ALBI score enhances prediction of hepatic decompensation in advanced chronic liver disease | Jaejun Lee | |
| THU-480 | High incidence and clinical relevance of concomitant Hepatopulmonary Syndrome among Patients with Portopulmonary Hypertension | Jendrik Peters | |
| WED-492 | Phase angle as a predictor of mortality in patients with liver cirrhosis | Lenka Nosáková | |
| WED-497 | Periprocedural bleeding in patients with cirrhosis: a prospective study | Adonis Protopapas | |
| FRI-498 | Warming up for success: controlled oxygenated rewarming prior to normothermic liver perfusion | Roberto Broere | |
| SAT-500 | Fairness-aware machine learning predicts 30-day mortality in vietnamese patients with decompensated cirrhosis | hien tran | |
| TOP-502 | Longitudinal assessment of body composition and its prognostic impact after TIPS in cirrhosis: a prospective multicenter study (NutriTIPS group) | Simone Di Cola | |
| TOP-504 | Liver and spleen stiffness measurements by vibration – controlled transient elastography predict liver-related outcomes of patients with porto-sinusoidal vascular disorder | Lucile Moga | |
| THU-505 | Decreases in spleen stiffness assessed via vibration-controlled transient elastography at 100Hz upon chronic NSBB treatment do not predict HVPG response: results from a european multicenter study | Paul Thöne | |
| WED-506 | Influence of albumin treatment duration on outcome of terlipressin therapy in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) | Eva Maria Schleicher | |
| FRI-508 | Continuous glucose monitoring in liver transplant recipients in the intensive care unit: a randomized clinical trial cohort | Richie Alexander Inge Cox | |
| THU-510 | Integrating gut microbiota and clinical parameters to predict beta-blocker response and portal pressure in patients with cirrhosis | Peishan wu | |
| WED-510 | Differentiation of minimal and grade 1 hepatic encephalopathy using neurophysiological, neuropsychological, magnetic resonance spectroscopic, and systemic inflammatory parameters | Barjesh Sharma | |
| THU-511 | Effects of early placement of transjugular portosystemic shunts in patients with gastric fundal variceal bleeding: a multicenter cohort study | Jie Xue | |
| FRI-511 | Sex-based inequities in liver transplant access associated with jaffe creatinine measurement bias: an analysis from the scientific registry of transplant recipients data | Eda Kaya | |
| SAT-512 | Potential of reflex testing with the CORE model triggered by liver enzyme abnormalities to improve risk prediction in the general population | Fredrik berg | |
| THU-515 | Interventional embolization of spontaneous portosystemic shunts improves survival by reducing further decompensation in selected patients with decompensated cirrhosis: a retrospective matched analysis | Hongbin Zhu | |
| TOP-520 | Rejection-associated transcripts distinguish between different types of rejection after liver transplantation | Alejandro Campos Murguía | |
| SAT-522 | Diagnostic performance of the ELF score for liver fibrosis staging in chronic liver disease: a comparative study with FibroScan, serum markers, and liver biopsy | Tatsuya Fujino | |
| WED-524 | Active smoking is linked to persisting systemic inflammation and higher mortality after TIPS | Tammo Tergast | |
| FRI-524 | Basiliximab preserves renal function after liver transplantation without increasing rejection or graft loss | Dorothy Liu | |
| FRI-525 | Time-adjusted analysis of cumulative immunosuppression and hepatocellular carcinoma recurrence risk after liver transplantation | Dorothy Liu | |
| FRI-526 | Multidisciplinary follow-up after liver transplantation: diagnostic yield and impact on cancer and cardiovascular outcomes | Erica Nicola Lynch | |
| FRI-528 | Outcomes of everolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma with or without steroid induction | Bianca Magro | |
| THU-529 | Glypican 3-targeted antigen-specific fluorescent imaging enhances real-time intraoperative tumor identification in hepatocellular carcinoma: a translational study | Shuhei Kanda | |
| FRI-529 | Who drops out? Preoperative prediction of hepatic hypertrophy techniques failure from the IGROWtoH registry | cecilia maina | |
| WED-529 | Severity at diagnosis and progression in chronic liver disease by aetiology: a nationwide cohort study of 146,654 individuals in Sweden, 2002–2022 | Juan Vaz | |
| SAT-530 | A machine learning approach to non-invasively predict hepatic decompensation in compensated advanced chronic liver disease: the CIRI model | Georg Kramer | |
| WED-531 | Optimal glycaemic targets to prevent major adverse cardiovascular events and risk of hypoglycaemia in patients with type 2 diabetes and cirrhosis | Mary Yue Wang | |
| SAT-531 | Association between small intestinal bacterial overgrowth and chronic liver disease in patients with functional gastrointestinal disorders: a cross-sectional study in southern Vietnam | Ngan Le Thanh Quynh | |
| TOP-535 | Barriers and facilitators in alcohol-related care pathways: findings from a qualitative interview study | Lea Ladegaard Grnkjr | |
| TOP-536 | Conceptual development of an advanced practice nurse role for patients living with liver cirrhosis in a Swiss health care system | Jasmin Herzog | |
| WED-537 | Targeted albumin therapy for recompensation in decompensated HBV-related cirrhosis: baseline characteristics of a multicenter randomized trial | Wanting Yang | |
| SAT-537 | Nurse-led clinics improve hepatocellular carcinoma surveillance rates and survival in patients with cirrhosis | Mohammad Malik | |
| FRI-538 | Cross-modality validation of 90% pathological response as a predictor of long-term survival in early-stage HCC | Mzamo Mbelle | |
| THU-546 | LivR Well 2.0 - Nourishing a hungry liver: interim results | Sophie Page | |
| WED-547 | FibroScan® insights: lifestyle change and liver health in primary biliary cholangitis | Louise Campbell | |
| FRI-547 | Accuracy, feasibility, and nursing workload of continuous glucose monitoring in liver transplant recipients in the intensive care unit | Marc Pañero Moreno | |
| SAT-549 | Prognostic value of handgrip strength in 1,294 japanese patients with liver cirrhosis: a large-scale multicenter cohort study from the NHO network | Hiroshi Yatsuhashi | |
| WED-549 | Feedback meetings as a method to involve patients with alcohol-related liver cirrhosis and their relatives | Marie Christiansen | |
| TOP-551 | Intrahepatic cccDNA Activity in HBsAg-Negative HBV Carriers and Its Association with HCC Risk | Yanfei Feng | |
| THU-553 | Early health-related quality of life decline and hypoalbuminaemia predict outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab | Masako Shomura | |
| THU-554 | Joint consultations during transition: perspectives of young adults with rare liver diseases | Janne Suykens | |
| THU-555 | Real-world nutritional management and outcomes in alcohol-associated hepatitis: a comparison of adherence to guidelines and short-term mortality between two centers | Erica Wajntraub Bakszt | |
| THU-556 | A review of terlipressin use in hepatorenal syndrome-acute kidney injury across 18 hospitals in the United Kingdom: Can we "CONFIRM" a change in practice? | (Leslie) Chun Man Wong | |
| FRI-558 | Excluding ascites from the GEMA-Na score does not impact outcome predictions in liver transplant candidates | Manuel Luis Rodriguez Peralvarez | |
| THU-558 | Small interfering RNA targeting all hepatitis B virus transcripts rapidly decreases the levels of hepatitis D virus in serum but not in the liver of HBV/HDV coinfected humanized mice | Johannes Bächer | |
| THU-559 | HDV propagates by hijacking a non-canonical, lysosome-derived exosomal pathway independent of HBV | Enkhtuul Batbold | |
| WED-560 | Improvement of patient satisfaction via implementation of a specialist nurse for patients with hepatocellular carcinoma – second interim analysis of the HCC care nurse pilot study | Larissa Pajancic | |
| THU-562 | Study on the immunomodulatory effects and mechanisms of the traditional chinese medicine formula Tiaoganbuxuyidu against HBV in mice | Fan-E Cheng | |
| SAT-564 | Management of chronic hepatitis B in people with human immunodeficiency virus infection in Europe: real-world evidence from Spain and Germany | PABLO RYAN | |
| TOP-566 | Hepatitis B core–related antigen predicts immune-active transition in HBeAg-negative indeterminate chronic hepatitis B | Hsing-Yu Yeh | |
| TOP-567 | AASLD–EASL zone ALT associated with higher risk of HCC and liver-related mortality inchronic hepatitis B patients | Tai-Chung Tseng | |
| THU-569 | The mechanism of HSP90AB1 binding to hepatitis B surface antigen driving the progression of HBV-related hepatocellular carcinoma through chaperone-mediated autophagy | Shuangsuo Dang | |
| SAT-572 | Durability of functional cure in chronic hepatitis B: a systematic review and meta-analysis | Yuxing Chen | |
| SAT-573 | Seroprevalence and clinical characteristics of hepatitis d virus infection in korean patients with chronic hepatitis B and HBV-related hepatocellular carcinoma | Gwang Hyeon Choi | |
| SAT-576 | Hepatitis B virus genotype distribution and viral load patterns in African immigrants to Canada | Curtis Cooper | |
| THU-585 | Bulevirtide treatment reduces bystander activation of CD8+ T cells in chronic hepatitis D virus infection | Reem Hoblos | |
| FRI-588 | Real-world effectiveness of antiviral therapy for chronic HBV infection in Africa: HEPSANET analysis | Kalisha Bheemraj | |
| THU-588 | Acute hepatitis E virus infection in asymptomatic blood donors is characterized by constrained intra-host diversity and temporal mutational signatures | Saskia Janshoff | |
| SAT-589 | High diagnostic value of transient elastography for the diagnosis of advanced fibrosis and cirrhosis in patients with hepatitis D virus infection | Anna Hahn | |
| FRI-591 | Peginterferon alfa-2b–based therapy achieves higher HBsAg Loss in high-risk chronic hepatitis B patients: a prospective multicenter cohort study | Shuangsuo Dang | |
| SAT-593 | Impact of cardiometabolic risk factors control in patients with chronic hepatitis B treated with nucleos(t)ide analogues | Karen Cheuk-Ying Ho | |
| WED-595 | Antiviral effect and safety of terbinafine in chronic hepatitis B: results of a phase 1b study | Diederick van Doorn | |
| SAT-602 | Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B | Jaejun Lee | |
| FRI-602 | Impact of the NTCP rs17556915 polymorphism on disease severity and bulevirtide treatment response in chronic hepatitis D: a multicentre real-world study | Yu Ri Im | |
| WED-605 | From cure to complexity: post-SVR liver and metabolic trajectories in diabetic patients | Clelia Asero | |
| THU-606 | Antisense oligonucleotide-based strategy to target hepatitis delta virus infections | Julie LUCIFORA | |
| FRI-606 | Pipecolic acid–associated amino acid remodeling predicts functional cure in nucleoside analogue–experienced chronic hepatitis B treated with pegylated interferon alpha plus programmed cell death protein 1 blockade | Yaping Li | |
| SAT-608 | Genetic diversification in hepatitis Delta antigen and ribozyme correlates with altered virological and biochemical markers and may inform novel therapeutic targets | Alessia Magnapera | |
| WED-610 | Cumulative metformin exposure and risk of hepatocellular carcinoma after hepatitis C cure in a multicentre cohort | Henar Calvo Sánchez | |
| WED-617 | Hepatic and extrahepatic malignancies in hepatitis C virus-infected patients with cirrhosis treated with direct-acting antivirals in long-term observation | Krystyna Dobrowolska | |
| WED-618 | Evaluation of clinical performance and utility of the combined HCV antigen-antibody assay (HCV Duo) | Tatsuya Fujino | |
| THU-621 | Verification and validation data of the CE-IVD marked AltoStar® HDV RT-PCR Kit 1.5 for monitoring HDV RNA viral load in plasma and serum samples | Karin ROTTENGATTER | |
| THU-622 | A novel human liver chimeric mouse model to study Hepatitis B virus DNA integration | Melina Schäfer | |
| THU-623 | Arrayed human and porcine ISG screens identify hepatitis E virus host restriction factors | Sarah Schlienkamp | |
| SAT-623 | Quantitative HBsAg identifies individuals unlikely to achieve spontaneous functional cure of chronic hepatitis B | Juan carlos Ruiz cobo | |
| WED-625 | The association of liver stiffness measurement with liver-related complications in chronic hepatitis C infection: a retrospective study in Thailand | Pemika Manassevee | |
| WED-626 | Hepatocellular carcinoma surveillance among chronic hepatitis C patients after successful sustained virologic response: a systematic review and meta-analysis of economic evaluation studies | Soe Thiha Maung | |
| THU-627 | Hepatocellular carcinoma is a viral reservoir during hepatitis C treatment with direct-acting antivirals | Mario Jorge Silva | |
| SAT-628 | Long-term risk of hepatocellular carcinoma in strictly defined immune tolerant patients with chronic hepatitis B - Results from the global RADICAL consortium | Lisa van Velsen | |
| THU-628 | The miR-4461–FGA regulatory axis characterises hepatitis B virus infection and HBV-related hepatocarcinogenesis | Masaya Sugiyama | |
| SAT-633 | The impact of longitudinal hepatitis B virus genotypic diversity and viral dynamics on hepatocellular carcinoma risk in chronic hepatitis B | Ding-Lian Wang | |
| WED-634 | HCV screening and prevalence among children with neonatal abstinence syndrome and their mothers - underserved at-risk populations in the era of HCV elimination | Caroline Schwarz | |
| SAT-637 | Integrated model nurse clinic reduces adverse pregnancy outcomes of pregnant women with chronic hepatitis B | Grace Wong | |
| WED-643 | COVID-19 pandemic had minimal impact on the effort spent on the enhancement programme of treatment coverage for all adult patients with chronic hepatitis C virus (HCV) infection | Grace Wong | |
| WED-644 | Impact of sustained virological response on the prognosis of patients with HCV-related cirrhosis: a large-scale multicenter cohort study from the pre-and post-DAA eras | Hiroshi Yatsuhashi | |
27-30 May, Barcelona

Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|
|